VPB0618 - Thrombosis-related circulating miR-16-5p is associated with disease severity in patients hospitalised for COVID-19

Monday, July 11, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: Virtual

Co-Author(s)

CE

Ceren Eyileten

Senior Researcher
Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, 02-091 Warsaw, Poland
Warsaw, Mazowieckie, Poland

Presenting Author(s)

Zofia Wicik, PhD

Senior Researcher
Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, 02-091 Warsaw, Poland
Warsaw, Mazowieckie, Poland

Co-Author(s)

SS

Sérgio Simões

Dr
Federal Institute of Espírito Santo
Sao Paulo, Sao Paulo, Brazil
DM

David Martins-Jr

Dr
Federal University of ABC
Sao Paulo, Sao Paulo, Brazil
DK

Disha Keshwani

Student
1. Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, 02-091 Warsaw, Poland
Warsaw, Mazowieckie, Poland
AS

Andleeb Shahzadi

Assistant Prof
Istanbul Cerrahpasa University
Istanbul, Istanbul, Turkey
JJ

Joanna Jarosz-Popek

PhD candidate
Medical University of Warsaw
Warsaw, Mazowieckie, Poland
MW

Marta Wolska

PhD candidate
Medical University of Warsaw
warsaw, Mazowieckie, Poland
KK

Krzysztof Klos

Prof
Military Institute of Medicine
warsaw, Mazowieckie, Poland
WW

Wojciech Wlodarczyk

Prof
Military Institute of Medicine
warsaw, Mazowieckie, Poland
DS

Dariusz Soldacki

Prof
medical university of warsaw
warsaw, Mazowieckie, Poland
AC

Andrzej Chcialowski

Prof
Military Institute of Medicine
warsaw, Mazowieckie, Poland
JS

Jolanta M. Siller-Matula

Professor
Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna,1090 Vienna, Austria
Vienna, Wien, Austria
MP

Marek Postula

Prof
Medical University of Warsaw
Warsaw, Mazowieckie, Poland

Background: SARS-CoV-2 tropism for the ACE2 receptor, along with the multifaceted inflammatory reaction, is likely to drive the generalized hypercoagulable state seen in patients with COVID-19.

Aims: We aimed identify microRNAs (miRNAs) play role in ACE2-related thrombosis in coronavirus infection and validated the expressions of those miRNAs in 79 hospitalized COVID-19 patients and 32 healthy volunteers and monitored miRNAs patterns during the acute phase of COVID-19, as well as the prognostic potential biomarker.

Methods: Using the original bioinformatic workflow and network medicine approaches we reanalyzed four coronavirus-related expression datasets and performed co-expression analysis focused on thrombosis and ACE2 related genes. Blood RNA; quality RNA was assessed: fluorometric assay; RT-PCR for miRNAs expression measurement.

Results: We identified EGFR, HSP90AA1, APP, TP53, PTEN, UBC, FN1, ELAVL1 and CALM1 as regulatory genes which could play a pivotal role in COVID-19 related thrombosis. We also found miR-16-5p, miR-27a-3p, Let-7b-5p and miR-155-5p as regulators in coagulation and thrombosis process. We observed in separate cohort of COVID-19 patients and healthy controls that (i) expression of miR-16-5p, miR-27a-3p and miR-155-5p increased during observation, compared to the baseline measurement; (ii) a low baseline miR-16-5p expression presents predictive utility in assessment of the hospital length of stay or death in follow-up as a composite endpoint (AUC:0.810, 95% CI, 0.71-0.91, p< 0.0001); (iii) low baseline expression of miR-16-5p and T2DM are independent predictors of increased length of stay or death according to a multivariate analysis (OR: 9.417; 95% CI, 2.647-33.506; p=0.0005 and OR: 6.257; 95% CI, 1.049-37.316; p=0.044).

Conclusion(s): This study enabled us to better characterize changes in gene expression and signaling pathways related to COVID-19 thrombosis. In this study we identified, characterized and validated miRNAs which could serve as novel, thrombosis-related biomarkers of the COVID-19, can be used for early stratification of patients and prediction of severity of infection development in an individual.